February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

January 29, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder

Basel, 29 January 2018 FDA grants Breakthrough Therapy Designation for Roche’s balovaptan in autism spectrum disorder Balovaptan has the potential to be the first pharmacotherapy to help improve core social interaction and communication in people with autism spectrum disorder Second FDA Breakthrough Therapy Designation for a Roche neuroscience medicine Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 26, 2018 Uncategorized

CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors

Basel, 26 January 2018 CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hemlibra may help reduce the burden of managing haemophilia A Roche... Read more

January 26, 2018 Licensing, IP, and Legal

Invitation to Roche's Virtual Pipeline Event

Basel, 26 January 2018 Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event in a... Read more

January 12, 2018 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more

January 12, 2018 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Basel, 12 January 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis First and only approved disease-modifying medicine for people in the European Union (EU) with early primary progressive multiple sclerosis (PPMS) An important new treatment option for people with active relapsing forms of... Read more